Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
68
SYRE Quote, Financials, Valuation and Earnings
Last price:
$43.00
Seasonality move
:
-6.34%
Day range:
$42.27 - $43.80
52-week range:
$10.91 - $45.76
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
701.12x
P/B ratio:
6.04x
Volume:
695.2K
Avg. volume:
682.2K
1-year change:
134.13%
Market cap:
$3.4B
Revenue:
--
EPS (TTM):
-$2.08
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SYRE
Spyre Therapeutics, Inc.
|
-- | -$0.80 | 315.28% | -9.26% | $58.57 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.6M | $0.14 | 15.84% | -39.29% | $31.80 |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$12.1M | -$1.95 | 59.92% | -15.51% | $38.88 |
|
PTCT
PTC Therapeutics, Inc.
|
$289.2M | -$0.15 | -80.75% | -52.54% | $87.57 |
|
TNDM
Tandem Diabetes Care, Inc.
|
$277.2M | -$0.09 | 3.86% | -77.52% | $29.50 |
|
TYRA
Tyra Biosciences, Inc.
|
-- | -$0.53 | -- | -17.55% | $49.29 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SYRE
Spyre Therapeutics, Inc.
|
$43.01 | $58.57 | $3.4B | -- | $0.00 | 0% | 701.12x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$24.56 | $31.80 | $4.2B | 10.73x | $0.00 | 0% | 3.89x |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$30.23 | $38.88 | $1.8B | 3.91x | $0.00 | 0% | 32.43x |
|
PTCT
PTC Therapeutics, Inc.
|
$68.19 | $87.57 | $5.5B | 8.81x | $0.00 | 0% | 3.27x |
|
TNDM
Tandem Diabetes Care, Inc.
|
$25.30 | $29.50 | $1.7B | -- | $0.00 | 0% | 1.68x |
|
TYRA
Tyra Biosciences, Inc.
|
$33.31 | $49.29 | $1.8B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SYRE
Spyre Therapeutics, Inc.
|
-- | 1.781 | -- | 12.89x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 2.900 | 1.15% | 3.40x |
|
AGIO
Agios Pharmaceuticals, Inc.
|
3.26% | 2.234 | 2.53% | 10.52x |
|
PTCT
PTC Therapeutics, Inc.
|
206.17% | 0.479 | 6.54% | 2.21x |
|
TNDM
Tandem Diabetes Care, Inc.
|
74.33% | 1.906 | 30.15% | 1.92x |
|
TYRA
Tyra Biosciences, Inc.
|
2.07% | 1.209 | 0.79% | 17.31x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SYRE
Spyre Therapeutics, Inc.
|
-- | -$57.2M | -25.86% | -25.86% | -- | -$44.6M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$16.8M | -$121.6M | -29.08% | -30.11% | -608.9% | -$97.3M |
|
PTCT
PTC Therapeutics, Inc.
|
$148.4M | -$81.6M | 2742.58% | -- | -49.57% | -$71.6M |
|
TNDM
Tandem Diabetes Care, Inc.
|
$167.5M | $8.3M | -32.45% | -121.88% | 2.86% | $3.1M |
|
TYRA
Tyra Biosciences, Inc.
|
-$131K | -$32.9M | -34% | -34.65% | -- | -$22.4M |
Spyre Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns SYRE or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Spyre Therapeutics, Inc.'s net margin of 96.33%. Spyre Therapeutics, Inc.'s return on equity of -25.86% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital SYRESpyre Therapeutics, Inc.-- -$0.69 $715.2M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About SYRE or ACAD?
Spyre Therapeutics, Inc. has a consensus price target of $58.57, signalling upside risk potential of 36.18%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.80 which suggests that it could grow by 29.48%. Given that Spyre Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Spyre Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRESpyre Therapeutics, Inc.16 0 0 ACADACADIA Pharmaceuticals, Inc.11 5 1 -
Is SYRE or ACAD More Risky?
Spyre Therapeutics, Inc. has a beta of 3.152, which suggesting that the stock is 215.196% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock SYRE or ACAD?
Spyre Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spyre Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRE or ACAD?
Spyre Therapeutics, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Spyre Therapeutics, Inc.'s net income of -$51.8M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Spyre Therapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 10.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spyre Therapeutics, Inc. is 701.12x versus 3.89x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRESpyre Therapeutics, Inc.701.12x -- -- -$51.8M ACADACADIA Pharmaceuticals, Inc.3.89x 10.73x $284M $273.6M
-
Which has Higher Returns SYRE or AGIO?
Agios Pharmaceuticals, Inc. has a net margin of -- compared to Spyre Therapeutics, Inc.'s net margin of -541.09%. Spyre Therapeutics, Inc.'s return on equity of -25.86% beat Agios Pharmaceuticals, Inc.'s return on equity of -30.11%.
Company Gross Margin Earnings Per Share Invested Capital SYRESpyre Therapeutics, Inc.-- -$0.69 $715.2M AGIOAgios Pharmaceuticals, Inc.84.25% -$1.85 $1.2B -
What do Analysts Say About SYRE or AGIO?
Spyre Therapeutics, Inc. has a consensus price target of $58.57, signalling upside risk potential of 36.18%. On the other hand Agios Pharmaceuticals, Inc. has an analysts' consensus of $38.88 which suggests that it could grow by 28.6%. Given that Spyre Therapeutics, Inc. has higher upside potential than Agios Pharmaceuticals, Inc., analysts believe Spyre Therapeutics, Inc. is more attractive than Agios Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRESpyre Therapeutics, Inc.16 0 0 AGIOAgios Pharmaceuticals, Inc.7 3 0 -
Is SYRE or AGIO More Risky?
Spyre Therapeutics, Inc. has a beta of 3.152, which suggesting that the stock is 215.196% more volatile than S&P 500. In comparison Agios Pharmaceuticals, Inc. has a beta of 0.915, suggesting its less volatile than the S&P 500 by 8.508%.
-
Which is a Better Dividend Stock SYRE or AGIO?
Spyre Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agios Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spyre Therapeutics, Inc. pays -- of its earnings as a dividend. Agios Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRE or AGIO?
Spyre Therapeutics, Inc. quarterly revenues are --, which are smaller than Agios Pharmaceuticals, Inc. quarterly revenues of $20M. Spyre Therapeutics, Inc.'s net income of -$51.8M is higher than Agios Pharmaceuticals, Inc.'s net income of -$108M. Notably, Spyre Therapeutics, Inc.'s price-to-earnings ratio is -- while Agios Pharmaceuticals, Inc.'s PE ratio is 3.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spyre Therapeutics, Inc. is 701.12x versus 32.43x for Agios Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRESpyre Therapeutics, Inc.701.12x -- -- -$51.8M AGIOAgios Pharmaceuticals, Inc.32.43x 3.91x $20M -$108M
-
Which has Higher Returns SYRE or PTCT?
PTC Therapeutics, Inc. has a net margin of -- compared to Spyre Therapeutics, Inc.'s net margin of -81.96%. Spyre Therapeutics, Inc.'s return on equity of -25.86% beat PTC Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SYRESpyre Therapeutics, Inc.-- -$0.69 $715.2M PTCTPTC Therapeutics, Inc.90.1% -$1.67 $193.4M -
What do Analysts Say About SYRE or PTCT?
Spyre Therapeutics, Inc. has a consensus price target of $58.57, signalling upside risk potential of 36.18%. On the other hand PTC Therapeutics, Inc. has an analysts' consensus of $87.57 which suggests that it could grow by 28.42%. Given that Spyre Therapeutics, Inc. has higher upside potential than PTC Therapeutics, Inc., analysts believe Spyre Therapeutics, Inc. is more attractive than PTC Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRESpyre Therapeutics, Inc.16 0 0 PTCTPTC Therapeutics, Inc.7 4 1 -
Is SYRE or PTCT More Risky?
Spyre Therapeutics, Inc. has a beta of 3.152, which suggesting that the stock is 215.196% more volatile than S&P 500. In comparison PTC Therapeutics, Inc. has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.641%.
-
Which is a Better Dividend Stock SYRE or PTCT?
Spyre Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spyre Therapeutics, Inc. pays -- of its earnings as a dividend. PTC Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRE or PTCT?
Spyre Therapeutics, Inc. quarterly revenues are --, which are smaller than PTC Therapeutics, Inc. quarterly revenues of $164.7M. Spyre Therapeutics, Inc.'s net income of -$51.8M is higher than PTC Therapeutics, Inc.'s net income of -$135M. Notably, Spyre Therapeutics, Inc.'s price-to-earnings ratio is -- while PTC Therapeutics, Inc.'s PE ratio is 8.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spyre Therapeutics, Inc. is 701.12x versus 3.27x for PTC Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRESpyre Therapeutics, Inc.701.12x -- -- -$51.8M PTCTPTC Therapeutics, Inc.3.27x 8.81x $164.7M -$135M
-
Which has Higher Returns SYRE or TNDM?
Tandem Diabetes Care, Inc. has a net margin of -- compared to Spyre Therapeutics, Inc.'s net margin of -0.2%. Spyre Therapeutics, Inc.'s return on equity of -25.86% beat Tandem Diabetes Care, Inc.'s return on equity of -121.88%.
Company Gross Margin Earnings Per Share Invested Capital SYRESpyre Therapeutics, Inc.-- -$0.69 $715.2M TNDMTandem Diabetes Care, Inc.57.67% -$0.01 $604.5M -
What do Analysts Say About SYRE or TNDM?
Spyre Therapeutics, Inc. has a consensus price target of $58.57, signalling upside risk potential of 36.18%. On the other hand Tandem Diabetes Care, Inc. has an analysts' consensus of $29.50 which suggests that it could grow by 16.6%. Given that Spyre Therapeutics, Inc. has higher upside potential than Tandem Diabetes Care, Inc., analysts believe Spyre Therapeutics, Inc. is more attractive than Tandem Diabetes Care, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRESpyre Therapeutics, Inc.16 0 0 TNDMTandem Diabetes Care, Inc.8 14 0 -
Is SYRE or TNDM More Risky?
Spyre Therapeutics, Inc. has a beta of 3.152, which suggesting that the stock is 215.196% more volatile than S&P 500. In comparison Tandem Diabetes Care, Inc. has a beta of 1.683, suggesting its more volatile than the S&P 500 by 68.285%.
-
Which is a Better Dividend Stock SYRE or TNDM?
Spyre Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spyre Therapeutics, Inc. pays -- of its earnings as a dividend. Tandem Diabetes Care, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRE or TNDM?
Spyre Therapeutics, Inc. quarterly revenues are --, which are smaller than Tandem Diabetes Care, Inc. quarterly revenues of $290.4M. Spyre Therapeutics, Inc.'s net income of -$51.8M is lower than Tandem Diabetes Care, Inc.'s net income of -$589K. Notably, Spyre Therapeutics, Inc.'s price-to-earnings ratio is -- while Tandem Diabetes Care, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spyre Therapeutics, Inc. is 701.12x versus 1.68x for Tandem Diabetes Care, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRESpyre Therapeutics, Inc.701.12x -- -- -$51.8M TNDMTandem Diabetes Care, Inc.1.68x -- $290.4M -$589K
-
Which has Higher Returns SYRE or TYRA?
Tyra Biosciences, Inc. has a net margin of -- compared to Spyre Therapeutics, Inc.'s net margin of --. Spyre Therapeutics, Inc.'s return on equity of -25.86% beat Tyra Biosciences, Inc.'s return on equity of -34.65%.
Company Gross Margin Earnings Per Share Invested Capital SYRESpyre Therapeutics, Inc.-- -$0.69 $715.2M TYRATyra Biosciences, Inc.-- -$0.50 $286.4M -
What do Analysts Say About SYRE or TYRA?
Spyre Therapeutics, Inc. has a consensus price target of $58.57, signalling upside risk potential of 36.18%. On the other hand Tyra Biosciences, Inc. has an analysts' consensus of $49.29 which suggests that it could grow by 47.98%. Given that Tyra Biosciences, Inc. has higher upside potential than Spyre Therapeutics, Inc., analysts believe Tyra Biosciences, Inc. is more attractive than Spyre Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRESpyre Therapeutics, Inc.16 0 0 TYRATyra Biosciences, Inc.9 0 0 -
Is SYRE or TYRA More Risky?
Spyre Therapeutics, Inc. has a beta of 3.152, which suggesting that the stock is 215.196% more volatile than S&P 500. In comparison Tyra Biosciences, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SYRE or TYRA?
Spyre Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tyra Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spyre Therapeutics, Inc. pays -- of its earnings as a dividend. Tyra Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRE or TYRA?
Spyre Therapeutics, Inc. quarterly revenues are --, which are smaller than Tyra Biosciences, Inc. quarterly revenues of --. Spyre Therapeutics, Inc.'s net income of -$51.8M is lower than Tyra Biosciences, Inc.'s net income of -$29.9M. Notably, Spyre Therapeutics, Inc.'s price-to-earnings ratio is -- while Tyra Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spyre Therapeutics, Inc. is 701.12x versus -- for Tyra Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRESpyre Therapeutics, Inc.701.12x -- -- -$51.8M TYRATyra Biosciences, Inc.-- -- -- -$29.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Feb 28
Applied Optoelectronics, Inc. [AAOI] is up 56.96% over the past day.
Buy
90
BNAI alert for Feb 28
Brand Engagement Network, Inc. [BNAI] is up 36.02% over the past day.
Sell
36
WLDN alert for Feb 28
Willdan Group, Inc. [WLDN] is down 25.56% over the past day.
